New drug combo hopes to tackle Hard-to-Treat cancers

NCT ID NCT07156253

Recruiting now Disease control Sponsor: Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This early-phase study tests a new oral drug called SYN818 combined with olaparib in 110 adults with advanced solid tumors, including ovarian and breast cancers that have BRCA mutations or related DNA repair problems. The main goals are to find a safe dose and check for side effects. Participants must have exhausted standard treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SYN818 and olaparib (oral drugs)
What this could lead to: If it works, this could point toward a new combination treatment for certain advanced cancers that have not responded to standard therapies.
What could go wrong: This is a very early Phase 1 study focused on safety and dosing, not yet on effectiveness. The combination may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autosomal recessive Kenny-Caffey syndrome breast cancer breast neoplasm Her2-receptor negative breast cancer metastatic malignant neoplasm Neoplasm Metastasis ovarian cancer ovarian carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS BRCA 1 /2 AND / OR HRD BREAST CANCER METASTATIC SOLID TUMOR OVARIAN CANCER

Contacts and locations

Locations

FuDan University Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, 200032, China
FuDan University Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.